GleamWall
中文EN

ARCT Arcturus Therapeutics Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1768224 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-68.7%
TTM net income YoY-30.8%
TTM EPS YoY-26.0%
Revenue 3-yr CAGR-53.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-311.2%
Net margin-285.9%
FCF margin-204.7%
EBITDA margin-302.9%

Returns

ROE-44.4%
ROA-35.1%
ROIC (approx.)-533.8%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets21.6%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue-0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.30M$2.96M$2.06M$7.20M$17.15M$28.30M$29.38M$22.77M
R&D expense$17.00M$17.52M$21.53M$24.48M$23.27M$29.58M$34.89M$43.78M
SG&A expense$10.48M$10.99M$9.46M$14.03M$10.40M$10.34M$11.31M$12.38M
Operating income-$9.19M-$25.55M-$28.93M-$31.31M-$16.51M-$11.62M-$16.83M-$33.39M
Pretax income-$7.41M-$23.79M—-$29.08M-$13.45M-$9.18M-$14.08M-$30.01M
Income tax$0$0——$0$4,000$0-$4,000
Net income-$7.41M-$23.79M-$26.96M-$29.08M-$13.45M-$9.18M-$14.08M-$30.00M
EBITDA-$8.59M-$24.95M-$28.27M-$30.62M-$15.71M-$10.82M-$16.02M-$32.58M
EPS (basic)-0.26-0.84-0.95—-0.49-0.34-0.52—
EPS (diluted)-0.26-0.84-0.95—-0.49-0.34-0.52—
Weighted avg. shares (diluted)28.44M28.42M28.42M—27.19M27.13M27.11M—
Balance sheet
Cash & equivalents$184.82M$191.48M$211.38M$230.91M$180.36M$196.47M$216.95M$293.91M
Receivables$1.25M$1.81M$1.34M$5.56M$7.95M$17.20M$14.57M$3.97M
Current assets$189.40M$197.16M$216.88M$241.45M$249.20M$274.50M$278.79M$305.98M
PP&E, net$4.81M$5.36M$6.08M$6.74M$7.42M$8.09M$8.87M$9.53M
Total assets$215.32M$224.31M$245.41M$271.15M$282.34M$309.27M$331.79M$344.07M
Current liabilities$28.34M$33.54M$34.37M$36.38M$31.70M$46.52M$49.41M$65.49M
Long-term debt——————$15.00M—
Total debt——————$15.00M—
Total liabilities$46.59M$52.50M$54.05M$57.16M$57.78M$78.22M$98.03M$103.09M
Shareholders' equity$168.73M$171.81M$191.36M$213.99M$224.56M$231.05M$233.76M$240.98M
Net debt——————-$201.95M—
Shares outstanding28.46M28.42M28.42M28.41M27.23M27.15M—27.00M
Cash flow statement
Operating cash flow-$6.91M-$19.91M-$19.44M-$16.23M-$17.15M-$5.75M-$35.14M-$284,000
Capital expenditure$52,000$0$0-$88,000$181,000$0$137,000$0
Free cash flow-$6.96M-$19.91M-$19.44M-$16.14M-$17.33M-$5.75M-$35.27M-$284,000
Investing cash flow-$52,000$18,000$34,000$88,000-$181,000$0-$137,000$0
Financing cash flow$291,000$0$16,000$11.69M$1.23M-$14.73M$15.20M$134,000
Depreciation & amortization$600,000$600,000$658,000$682,000$800,000$800,000$801,000$819,000
Stock-based compensation$4.04M$4.23M$4.33M$6.82M$5.73M$6.20M$6.66M$8.98M

Free plan shows the latest 8 periods; Pro shows all 34 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.